Kite announces plans to build industry-leading cell therapy manufacturing capabilities with a new viral vector facility in Oceanside, California.
A new state-of-the-art 67,000 square feet building will be constructed inside Gilead’s existing facility.
The new facility will manufacture the viral vectors such as replication-deficient gamma-retroviral vector PG13-CD19-H3 and replication-deficient lentiviral vector.
PG13-CD19-H3 is the important initial material used for production of Yescarta. It was the company’s first Chimeric Antigen Receptor (CAR) T-cell therapy that is used for treatment of large B-cell lymphoma in adult patients.
Yescarta extracts white blood cells (WBCs) from the patient's body and differentiate T-cells from the WBCs to modify and re-use them into patient's body to identify and kill the cancer cells.
The retroviral vector PG13-CD19-H3 is also used for development of other investigational therapies such as KTE-X19 for acute lymphocytic leukaemia and mantle cell lymphoma. The facility also supports the investigational biologic production of KITE-585 and KITE-718 therapy.
|Kite, a Gilead Company
|Oceanside, California, USA